FGFR2 amplification in metastatic hormone-positive breast cancer and response to an mTOR inhibitor

Ann Oncol. 2017 Aug 1;28(8):2025-2027. doi: 10.1093/annonc/mdx194.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Androstadienes / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / genetics*
  • Breast Neoplasms / metabolism
  • Estradiol / administration & dosage
  • Estradiol / analogs & derivatives
  • Everolimus / administration & dosage
  • Female
  • Fulvestrant
  • Gene Amplification
  • Goserelin / administration & dosage
  • Humans
  • Piperazines / administration & dosage
  • Pyridines / administration & dosage
  • Receptor, Fibroblast Growth Factor, Type 2 / genetics*
  • Receptors, Estrogen / metabolism
  • Receptors, Progesterone / metabolism
  • TOR Serine-Threonine Kinases / antagonists & inhibitors*
  • Tamoxifen / administration & dosage

Substances

  • Androstadienes
  • Piperazines
  • Pyridines
  • Receptors, Estrogen
  • Receptors, Progesterone
  • Tamoxifen
  • Goserelin
  • Fulvestrant
  • Estradiol
  • Everolimus
  • MTOR protein, human
  • FGFR2 protein, human
  • Receptor, Fibroblast Growth Factor, Type 2
  • TOR Serine-Threonine Kinases
  • palbociclib
  • exemestane